Company Overview and News

Top MLP Gainers in the Week Ending April 13

2018-04-17 marketrealist
Legacy Reserves (LGCY), an upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP gainer in the week ending April 13, 2018. Legacy Reserves rallied 17.4% last week. The rally was mainly due to strong gains in crude oil prices.
Upvote Downvote

A 10% Yield, 11 Straight Hikes, No K-1, IDR Swap Deal Coming In Q2, Goes Ex-Dividend Soon

2018-04-14 seekingalpha
The parent/GP is consolidating in Q2, is eliminating the GP and IDR payouts, and raised its upcoming quarterly payout by 37%.
Upvote Downvote

AMN Healthcare stock price target raised to $66 from $60 at Benchmark

2018-04-10 marketwatch
AMN Healthcare Services Inc (AMN) CEO Susan Salka on Q4 2017 Results - Earnings Call Transcript
Upvote Downvote

A 10% Yield, 20 Straight Distribution Hikes, Big Deal Adding More Growth In 2018

2018-04-07 seekingalpha
Are you a patient income investor willing to wait out the challenges which the market may throw your way, as you monitor your portfolio? Holders of midstream and shipping LPs, REITs, and other high-yield entities have been tested over the past few months, as these vehicles have been put in the garage by Mr. Market.
Upvote Downvote

How Safe Is The Dividend Of Summit Midstream Partners?

2018-03-20 seekingalpha
As the market does not offer such a high yield for free, the big question is how safe this dividend is.
Upvote Downvote

High-Yield Midstream Pipeline 2017 Earnings Roundup

2018-03-18 seekingalpha
This group of midstream pipeline LPs yields range from more than 6% to more than 14%.
Upvote Downvote

BRIEF-Summit Midstream Partners Responds To FERC Announcement

2018-03-16 reuters
Upvote Downvote

Last Week’s Worst MLP Performers

Summit Midstream Partners (SMLP), a midstream MLP mainly involved in natural gas gathering, processing, and compression, was the worst MLP performer last week. It fell 4.5%. The partnership has lost 22.4% since the start of this year. SMLP’s recent weakness could be due to its weak 4Q17 earnings. The partnership posted flat adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) of $72.
Upvote Downvote

Which Energy Stocks Were the Underperformers Last Week?

On March 2–9, 2018, midstream stock Summit Midstream Partners (SMLP) fell the most on our list of energy stocks.
Upvote Downvote

A Contrarian 14% Yield Play, With 1.59X Coverage, 8% Below Lowest Price Target

2018-03-03 seekingalpha
Management says coverage should be strong again in Q1, but will average 1X in 2018, due to higher capex costs for projects.
Upvote Downvote

SMLP / Summit Midstream Partners LP 8-K (Current Report)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2018 Summit Midstream Partners, LP (Exact name of registrant as specified in its charter) Delaware 001-35666 45-5200503 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.
Upvote Downvote

Last Week’s Biggest MLP Losers: SMLP and More

Summit Midstream Partners (SMLP), a midstream MLP mainly involved in crude oil gathering and processing and crude oil gathering, was the biggest MLP loser last week. SMLP fell 8.9% in a single trading session on Friday, resulting in a weekly loss of 12.7%.
Upvote Downvote

SMLP / Summit Midstream Partners LP SMLP 2017 FORM 10-K (Annual Report)

Upvote Downvote

Which Energy Stocks Fell the Most Last Week?

On February 16–23, 2018, oilfield service stock U.S. Silica Holdings (SLCA) fell the most on our list of energy stocks. However, the VanEck Vectors Oil Services ETF (OIH) rose 2.2% during this period.
Upvote Downvote

Risen From The Ashes - Outperforming LP Still Yields 12%, Big Growth In 2018

2018-02-25 seekingalpha
Many more growth projects are due to come online in 2018; will ramp up earnings growth further.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 866142102